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ABSTRACT 25 
Neonicotinoids are one of most widely used pesticides targeting nicotinic acetylcholine 26 
receptors (nAChRs) of insects. Recent epidemiological evidence revealed increasing amounts 27 
of neonicotinoids detected in human samples, raising the critical question of whether 28 
neonicotinoids affect human health. We investigated the effects of a neonicotinoid pesticide 29 
clothianidin (CTD) on human neuroblastoma SH-SY5Y cells as in vitro models of human 30 
neuronal cells. Cellular and functional effects of micromolar doses of CTD were evaluated by 31 
changes in cell growth, intracellular signaling activities and gene expression profiles. We 32 
examined further the effects of CTD on neuronal differentiation by measuring neurite 33 
outgrowth. Exposure to CTD (1–100 µM) significantly increased the number of cells within 34 
24 hours of culture. The nAChRs antagonists, mecamylamine and SR16584, inhibited this 35 
effect, suggesting human α3β4 nAChRs could be targets of neonicotinoids. We observed a 36 
transient intracellular calcium influx and increased phosphorylation of extracellular 37 
signal-regulated kinase 1/2 shortly after exposure to CTD. Transcriptome analysis revealed 38 
that CTD down-regulated genes involved in neuronal function (e.g., formation of filopodia 39 
and calcium ion influx) and morphology (e.g., axon guidance signaling and cytoskeleton 40 
signaling); these changes were reflected by a finding of increased neurite length during 41 
neuronal differentiation. These findings provide novel insight into the potential risks of 42 
neonicotinoids to the human nervous system. 43 
 44 
Keywords: Neonicotinoid; Pesticide; Clothianidin; Neuroblastoma cell; Nicotinic 45 
acetylcholine receptor; Intracellular signaling. 46 
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1. Introduction 47 
Neonicotinoids are the most recent and widely used class of pesticides to control harmful 48 
insects in the world. With expanding use of the pesticides in farming, multiple neonicotinoids 49 
are present in most vegetables, fruits and crops at parts-per-billion concentrations (Chen et al., 50 
2014; Ikenaka et al., 2018). In fact, neonicotinoids were detected in urine samples from most 51 
adults and children (Ueyama et al., 2015; Ikenaka et al., 2019) and the urinary concentration 52 
of total neonicotinoids in Japanese children has been reported to be in the hundreds-level 53 
nanomolar (Osaka et al., 2016). Neonicotinoids act as nicotinic acetylcholine receptor 54 
(nAChR) agonists with as much as hundreds fold greater affinity for insect nAChRs than for 55 
mammalian receptors (Tomizawa and Casida, 2005); however, adverse effects on 56 
physiological function of non-target vertebrates have been reported over the last decade 57 
(Hoshi et al., 2014; Gibbons et al., 2015; Wang et al., 2018). In vitro studies have shown that 58 
potency and specificity for mammalian nAChRs are critically different among types of 59 
neonicotinoids (Casida, 2018). In particular, Kimura-Kuroda et al. (2012) firstly showed that 60 
acetamiprid (ACE) and imidacloprid (IMI), earlier chloropyridylmethyl neonicotinoids, 61 
caused neural excitation in cerebellar cells from neonatal rats mediated by nAChRs. These 62 
ligand-gated ion channel receptors play a variety of roles in multiple areas of the mammalian 63 
brain, including not only cholinergic transmission but also neural excitability and synaptic 64 
plasticity (Gotti, et al., 2006; Dani and Bertrand, 2007). Thus, there is increasing concern 65 
about the risks of neonicotinoids on the central nervous system in mammals. 66 
 Recent rodent studies indicated that a variety of neonicotinoids have neurobehavioral 67 
effects on mammals depending on the timing of exposure. We previously reported that at or 68 
below the no observed adverse effect level (NOAEL) of a later-developed 69 
chlorothiazolylmethyl neonicotinoid, clothianidin (CTD) resulted in anxiety-like behavior 70 
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and human-audible vocalization in a novel environment in mature mice (Hirano et al., 2015, 71 
2018). Gestational and postnatal exposure of an early-type of neonicotinoid, ACE induced 72 
behavioral changes including increasing of sexual and attacking behavior in mature offspring 73 
(Sano et al., 2016), whereas IMI decreased social aggression behavior (Burke et al., 2018). In 74 
addition, pre- and postnatal exposure to the latest neonicotinoid, dinotefuran increased the 75 
number of dopaminergic and serotonergic neurons in the midbrain of mature mice (Takada et 76 
al., 2018; Yoneda et al., 2018). Although no common effects associated with the 77 
developmental neurotoxicity were observed among neonicotinoids (Sheets et al., 2016), 78 
differentiative neurons in the mammalian developing brain could be a potential target of 79 
neonicotinoids. 80 
It has been noted that the amount and detection rate of neonicotinoids in human-derived 81 
samples are increasing gradually every year (Ueyama et al., 2015). Although human 82 
population studies reported that environmental exposure to neonicotinoids associated with 83 
adverse neurological outcomes such as memory loss and finger tremor, experimental studies 84 
of risks of neonicotinoids in humans are still far from sufficient (Cimino et al., 2017). Most 85 
toxicological data for evaluating the effects of neonicotinoids were obtained from in vitro and 86 
in vivo studies using rats and mice as animal models; however, there are evolutionary 87 
differences in the amino acid sequence of nAChRs subunits between rodents and human 88 
(Tsunoyama and Gojobori, 1998; Stokes et al., 2015). Therefore, the intensity and dose 89 
responses of nAChRs to nicotinic agonists can be different across species (Papke and Porter 90 
Papke, 2002; Anderson et al., 2008), suggesting that there is some uncertainty to predict the 91 
risk of modulating the function of human-type nAChRs from other species.  92 
In the present study, we focused on CTD which has been banned in the European Union 93 
since 2013; however, it became a first-line pesticide for farming in many countries. 94 
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Intraperitoneally-administered CTD was immediately absorbed and reached throughout the 95 
body in mice including the brain at least a few hours (Ford and Casida, 2006). The aim of the 96 
present study is to provide novel experimental data for assessing whether CTD could affect 97 
human nervous system structure or function, using a human neuroblastoma cell line 98 
SH-SY5Y cells known to have high expression levels of neuronal types of nAChRs that 99 
contain α3, α7, β2, and β4 subunits (Lukas et al., 1993; Groot Kormelink and Luyten, 1997; 100 
Kovalevich and Langford, 2013) instead of animal models. We investigated the potential 101 
effects of CTD on cell growth and development, and examined mechanisms of action 102 
focusing on intracellular signaling and gene expression profiles. 103 
 104 
2. Materials and methods 105 
2.1. Cell culture and chemical treatments 106 
Human neuroblastoma SH-SY5Y cells (ECACC, No. 94030304) were maintained in 107 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS), 100 108 
U/ml penicillin and 100 µg/ml streptomycin at 37°C in humidified air with 5% CO2. 109 
Clothianidin (CTD; purity > 99.8%; Sigma-Aldrich, St. Louis, MO, USA), 110 
dihydro-β-erythroidine hydrobromide (DHβE; Tocris Bioscience, Ellisville, MO, USA) and 111 
SR 16584 (Cayman Chemical Co., Ann Arbor, MI, USA) were dissolved in dimethyl 112 
sulfoxide (DMSO). Mecamylamine hydrochloride (MEC; Sigma-Aldrich) and 113 
methyllycaconitine citrate (MLA; Cayman Chemical Co.) were dissolved in sterilized water. 114 
In all experiments, cells treated with corresponding vehicle (0.1% v/v) were used as a control. 115 
 116 
2.2. Cell growth assay 117 
For cell counting assays, cells were subcultured in 12-well plates at a seeding density 5.0 × 118 
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10
4
 cells/mL with 1 mL of the culture medium for 24 h, and then exposed to 1 or 100 µM 119 
CTD with reference to previous in vitro studies (Kimura-Kuroda et al., 2012; Christen et al., 120 
2017). After washing once with phosphate-buffered saline (PBS) and subsequent 121 
trypsinization, the number of cells was counted using a hematocytometer on Day 1 and 2. For 122 
antagonist assays, cells were exposed to nAChR antagonists concomitantly with 100 µM 123 
CTD and counted on Day 1. For microplate assays, cells were plated into 96-well plates at a 124 
seeding density 5.0 × 10
4
 cells/mL with 100 µL of the culture medium for 24 h, and then 125 
exposed to various concentrations of CTD (1 nM to 100 µM) for 24 h. Cells were then 126 
incubated with 127 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 128 
(WST-8; Dojindo Laboratories, Kumamoto, Japan) solution for 3 h and the absorbance at 450 129 
nm was measured by a BioRad 680 microplate reader (BioRad, Hercules, CA, USA). 130 
 131 
2.3. Fluo-4 calcium flux assay 132 
Changes in intracellular calcium concentration were measured with a fluo-4 kit (Dojindo 133 
Laboratories) according to the manufacturer’s instructions. Briefly, semi-confluent cells in a 134 
96-well microplate were loaded with 10 µM Fluo-4 AM in 100 µL of recording buffer [20 135 
mM HEPES buffer containing 115 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 136 
13.8 mM glucose] and 0.02% Pluronic F-127 for 60 min at 37°C. Cells were washed with 137 
PBS, and then 90 µL of the recording buffer was added. After measuring baseline 138 
fluorescence for 1 min, test compounds dissolved in the recording buffer (10 µL) were added 139 
and changes in fluorescence (excitation 488 nm; emission 530 nm) were kinetically measured 140 
by a microplate reader (SpectraMax i3, Molecular Devices, Sunnyvale, CA, USA) for 2 min. 141 
 142 
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2.4. Western blotting 143 
After 1 h of CTD treatment, semi-confluent cells were dissolved in ice-cold lysis buffer [50 144 
mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl and 1% NP-40, supplemented with 145 
1:1000 protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma-Aldrich)] and 146 
homogenized by an ultrasonic disruptor. Total protein concentrations of supernatant were 147 
determined using a Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, 148 
USA), and then equal amounts of proteins from each sample were boiled in SDS sample 149 
buffer [in final concentrations of 60 mM Tris /HCl, 10% glycerol, 2% SDS, 5% 150 
mercaptoethanol, 0.025% bromophenol blue, pH 6.8] at 94°C for 5 min. Samples containing 151 
10 µg of protein extract were separated in SDS-polyacrylamide gels and transferred to PVDF 152 
membranes. Membranes were blocked by PVDF Blocking Reagent for Can Get Signal 153 
(Toyobo Co., Ltd., Osaka, Japan) for 2 h at room temperature, and then incubated overnight 154 
at 4°C in Can Get Signal Immunoreaction Enhancer Solution 1 (Toyobo Co., Ltd.) with the 155 
rabbit anti-pERK antibody and mouse anti-ERK antibody (1:2000, #9101 and #9107, Cell 156 
Signaling Technology, Danvers, MA, USA). After washing 3 times with Tris-buffered saline 157 
containing 0.1% Tween 20, membranes were then incubated in Can Get Signal 158 
Immunoreaction Enhancer Solution 2 (Toyobo Co., Ltd.) with IRDye 680RD donkey 159 
anti-mouse IgG and IRDye 800CW goat anti-mouse IgG (1:2000; LI-COR Biosciences, 160 
Lincoln, NE, USA) for 2 h at room temperature. The Odyssey infrared imaging system 161 
(LI-COR Biosciences) was used to scan the infrared signal on membranes, and Image Studio 162 
5.1 software (LI-COR Biosciences) was used to quantify the band intensity. 163 
 164 
2.5. RNA isolation and Clariom S assay 165 
After 24 h of 1 µM CTD treatment, total RNA was extracted from semi-confluent cells 166 
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using a NucleoSpin plus RNA isolation kit (Macherey-Nagel GmbH & Co., Düren, Germany) 167 
following the manufacturer’s instructions. The quality of the RNA was analyzed using a 168 
Bioanalyzer 2100 and an RNA6000 Nano LabChip kit (Agilent Technologies, Inc., Santa 169 
Clara, CA, USA) and samples with RIN (RNA integrity number) values above 9.8 were 170 
considered acceptable. All RNA samples (500 ng) were amplified and labeled using the 171 
GeneChip WT PLUS Reagent Kit and hybridized with the Clariom S human arrays 172 
containing 21,448 probe sets (Affymetrix, Inc., Santa Clara, CA, USA). All microarrays were 173 
washed and stained on the GeneChip Fluidics Station 450 using the GeneChip Hybridization, 174 
Wash, and Stain Kit, and then scanned on the GeneChip Scanner 3000 (Affymetrix, Inc.). The 175 
raw intensity data were normalized and analyzed using GeneSpring GX 14.9 software 176 
(Agilent Technologies, Inc.). To examine the molecular functions of differentially expressed 177 
genes, data were analyzed using Ingenuity Pathways Analysis (IPA) tools (Ingenuity Systems, 178 
Mountain View, CA, USA). The microarray data (.CEL files) were deposited in a public 179 
database (Gene Expression Omnibus, accession number: GSE126103). 180 
 181 
2.6. Quantitative reverse transcription PCR 182 
RNA samples (1 µg) were reverse-transcribed to cDNA using a PrimeScript RT Master 183 
Mix (Takara Bio Inc., Shiga, Japan) following the manufacturer’s instructions. Gene 184 
expression was quantified using SYBR Green Premix Ex Taq II (Takara Bio Inc.) with 185 
specific primers (Table 1) on an Mx3005P Real-Time QPCR System (Agilent Technologies, 186 
Inc.). Cycling conditions were as follows: An initial degeneration of 95°C for 30 sec, 187 
followed by 40 cycles of denaturing at 95°C for 5 sec, annealing at 55°C for 30 sec, and 188 
elongation at 72°C for 30 sec. Copy number of genes were calculated by standard curves and 189 
the relative gene expression levels are normalized by a housekeeping gene, 190 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a MxPro software (version 4.10, 191 
Agilent Technologies, Inc.). All samples were measured in duplicate and the specificity of the 192 
PCR products was confirmed by melting curves. 193 
 194 
2.7. Neurite outgrowth assay 195 
Cells were plated on glass coverslips precoated with poly-L-lysine in 24-well plates at a 196 
seeding density of 5.0 × 10
4
 cells/mL with 500 µL of the culture medium. For differentiation, 197 
cells were treated with FBS-free DMEM containing 10 μM all-trans retinoic acid 198 
(Sigma-Aldrich) for 3 days, followed by FBS-free DMEM containing 50 ng/mL of 199 
brain-derived neurotrophic factor (Alomone lab, Jerusalem, Israel) for 3 days with or without 200 
1 or 100 µM CTD. After washing with PBS, cells were immediately fixed by 4% 201 
paraformaldehyde for 10 min and then permeabilized in 0.1% Triton-X in PBS for 10 min. 202 
Cells were blocked for 1 h with Blocking One Histo (Nacalai Tesque, Inc., Kyoto, Japan) and 203 
then incubated overnight at 4°C in Can Get Signal Immunoreaction Enhancer Solution A 204 
(Toyobo Co., Ltd.) with rabbit anti-MAP2 antibody (1:200, #4542, Cell Signaling 205 
Technology). After washing 3 times with PBS containing 0.1% Tween 20, cells were 206 
incubated for 2 h in Can Get Signal Immunoreaction Enhancer Solution B (Toyobo Co., Ltd.) 207 
with anti-rabbit donkey IgG (H&L) antibody conjugated to DyLight 549 (1:1000, 208 
#611-742-127, Rockland Immunochemicals, Inc., Gilbertsville, PA, USA). Cell nucleus was 209 
counterstained with 4’-6-diamidino-2- phenylindole (DAPI). The coverslips were mounted on 210 
microscope slides in ProLong Glass antifade mountant (Thermo Fisher Scientific, Waltham, 211 
MA, USA) and fluorescence images were acquired with a BX61/DP70 microscope (Olympus, 212 
Tokyo, Japan). Neurite length was measured in at least 100 cells in three randomly chosen 213 
fields using ImageJ software (version 1.51) with the NeuronJ plugin. 214 
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 215 
2.8. Statistical analyses 216 
Results from at least three independent experiments are expressed as the mean ± standard 217 
deviation (SD). IBM SPSS statistics 23 software (IBM Co., Somers, NY, USA) was used to 218 
perform statistical analyses. The dose-response curve was fitted using the sigmoidal 219 
(4-parameter) equation with JMP13 Pro software (SAS Institute, Cary, NC, USA). The EC50 220 
value was calculated by determining the concentration at which 50% of maximum activity 221 
was reached using the sigmoidal fit equation. One-way analysis of variance (ANOVA) 222 
followed by Dunnett’s post-hoc test was used to analyze the effects of CTD. Two-way 223 
ANOVA followed by Tukey’s post hoc test was used to analyze the interaction between CTD 224 
and nAChR antagonists. The Welch’s t test was used to validate the microarray results by 225 
quantitative reverse transcription PCR. The results were considered significant when the 226 
p-value was less than 0.05. 227 
 228 
3. Result 229 
3.1. Effects of CTD on the cell number of SH-SY5Y cells 230 
To determine the potential effects of CTD on human neuroblastoma SH-SY5Y cells, the 231 
cell growth assays were conducted. As shown in Fig. 1A, CTD dose-dependently stimulated 232 
the cell growth and one-way ANOVA showed that there were significant differences at Day 1 233 
[F(2, 12) = 11.150, p < 0.01] and Day 2 [F(2, 12) = 5.764, p < 0.05]. The high concentration 234 
of CTD (100 µM) significantly increased the relative cell number at Day 1 (p < 0.01) and 235 
Day 2 (p < 0.05). Low concentrations of CTD (1 µM) also increased the relative cell number 236 
at Day 1 (p < 0.05), but not significantly at Day 2. The dose-response relationship between 237 
the exposure concentration and the growth stimulating effect of CTD was evaluated by the 238 
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WST-8 assay. The dose-response curves showed that CTD had growth stimulating effects on 239 
SH-SY5Y cells with an EC50 of 577 nM (Fig. 1B).  240 
 241 
3.2. Antagonists to nAChR blocked the growth stimulating effect of CTD on SH-SY5Y cells 242 
We therefore investigated whether the effects of CTD on the SH-SY5Y cells were 243 
mediated by human-type nAChRs. Although 10 µM mecamylamine (MEC), a broad 244 
spectrum non-competitive nAChRs antagonist, had no effect on the SH-SY5Y cells alone, it 245 
inhibited the growth stimulating effect of 100 µM CTD (Fig. 2A). Two-way ANOVA showed 246 
that there was no effect of MEC [F(1, 16) = 3.295] and significant effect of CTD [F(1, 16) = 247 
7.853, p < 0.05] and significant interaction [F(1, 16) = 12.887, p < 0.01]. According to a 248 
previous report showing that SH-SY5Y cells are known to express α3, α7, β2 and β4 subunit 249 
of nAChRs (Groot Kormelink and Luyten, 1997), we further examined which subunit of 250 
nAChRs is involved in the effects of CTD with using subunit specific competitive nAChR 251 
antagonists. As shown in Fig. 2B and 2C, the α7 and β2 subunit specific antagonists 252 
methyllycaconitine (MLA, 100 nM) and dihydro-β-erythroidine (DHβE, 10 µM) did not 253 
suppress the effects of CTD. There was no effect of antagonists [MLA: F(1, 16) = 1.964; 254 
DHβE: F(1, 16) = 4.191], and significant effects of CTD were observed [MLA: F(1, 16) = 255 
15.817, p < 0.01; DHβE: F(1, 16) = 16.005, p < 0.01]. No interaction was detected between 256 
CTD and antagonists [MLA: F(1, 16) = 4.743; DHβE: F(1, 16) = 0.009]. In contrast, an α3β4 257 
specific antagonist, SR 16584 (10 µM), blocked the effect induced by 100 µM CTD (Fig. 2D). 258 
Two-way ANOVA showed that there was no effect of SR 16584 [F(1, 16) = 2.602] and 259 
significant effect of CTD [F(1, 16) = 10.179, p < 0.05] and significant interaction [F(1, 16) = 260 
8.312, p < 0.05]. 261 
 262 
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3.3. CTD evoked intracellular calcium flux in SH-SY5Y cells 263 
As nAChRs are ligand-gated ion channels permeable to calcium ions, we next evaluate the 264 
CTD-induced changes of intracellular calcium levels in SH-SY5Y cells loaded with 265 
calcium-sensitive dye Fluo-4 AM. The temporal changes of intracellular calcium levels were 266 
monitored by fluorescence intensity of fluo-4 (F) normalized to the average of baseline 267 
intensity (F0). As shown in Fig. 3A, transient increases of fluorescence intensity were 268 
observed immediately after exposure to CTD. Quantitative analyses showed that both the 269 
maximum amplitude (Fmax-F0) [F(3, 11) = 5.674, p < 0.05] and the area under the curve 270 
[F(3, 11) = 8.415, p < 0.01] were significantly increased by at least 10 µM of CTD (Fig. 3B 271 
and 3C).  272 
 273 
3.4. Effects of CTD on phosphorylation levels of ERK in SH-SY5Y cells 274 
To examine the modulation of the intracellular signaling subsequent to intracellular 275 
calcium influx induced by CTD, we analyzed phosphorylation levels of extracellular 276 
signal-regulated kinase 1/2 (ERK), which is known to be important in proliferation of 277 
neuroblastoma cells (Stafman and Beierle, 2016). SH-SY5Y cells were exposed to CTD for 1 278 
h, and total and phosphorylated ERK were detected on the same membrane at once by 279 
western blotting. As shown in Fig. 4A, although the band intensity of total ERK did not 280 
change, CTD increased that of phosphorylated ERK (p-ERK) compared to the control 281 
samples. Quantitative analyses showed that CTD dose-dependently and significantly 282 
increased the p-ERK/ERK ratio [F(3, 11) = 4.053, p < 0.05] (Fig. 4B). 283 
 284 
3.5. Effects of CTD on global gene expression of SH-SY5Y cells 285 
To understand changes of gene expression involved in the mechanisms of effects of CTD, 286 
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the transcriptome analysis was performed in cells exposed to 1 µM CTD for 24 h using 287 
GeneChip system and the clariom S human array with 21,448 probe sets. After normalization 288 
of obtained intensities of probes using the RMA algorithm using the GeneSpring software, 289 
low intensity probes (<10% expression level) were cutoff as noise. We then identified 290 
differentially expressed genes (174 up-regulated and 151 down-regulated) with at least 291 
1.5-fold change compared with the control group (0.1% DMSO), and then conducted 292 
bioinformatical analyses to reveal biological functions, canonical pathways, and networks of 293 
differentially expressed genes based on Ingenuity Pathway Analysis (IPA) knowledge base 294 
software. We obtained little findings related to the phenotypic changes observed in this study 295 
from up-regulated genes (Supplemental Materials). The top 25 biological functions with 296 
positive z-scores related to the down-regulated genes are summarized in Table 2. Notably, 297 
CTD significantly decreased the expression of genes associated with neural functions with 298 
annotations of “Formation of filopodia,” “Brain lesion,” “Quantity of neurons,” “Behavior,” 299 
and “Differentiation of nervous system.” Additionally, multiple annotations associated with 300 
calcium signaling, “Flux of Ca
2+
,” “Influx of Ca
2+
,” and “Ion homeostasis of cells,” were also 301 
listed. The differentially activated or suppressed canonical pathways in down-regulated genes 302 
are shown in Fig. 5A. Canonical pathways including “Axonal Guidance Signaling” and 303 
“Synaptic Long Term Depression” relating to neural function were enriched in 304 
down-regulated genes. Cytoskeletal pathways,“Gα12/13 Signaling,” “PAK Signaling,” 305 
“Actin Cytoskeleton Signaling,” and “Signaling by Rho Family GTPases,” were significantly 306 
suppressed. Network analyses revealed gene networks with 40 molecules involved in 307 
“Cardiovascular System Development and Function,” “Organismal Development” and 308 
“Cell-To-Cell Signaling and Interaction” (Fig. 5B) and several down-regulated genes 309 
indirectly affected signal transduction molecules such as ERK, ras-related protein 1 (Rap1) 310 
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and cAMP response element binding protein (Creb). 311 
 312 
3.6. Validation of microarray results by quantitative reverse transcription PCR 313 
To confirm the microarray results, the expression levels of down-regulated genes were 314 
measured by quantitative reverse transcription PCR. We chose three genes significant in the 315 
bioinformatical analyses by the IPA software including neuronal differentiation 4 316 
(NEUROD4), adrenoceptor beta 2 (ADRB2), and neurotensin (NTS). As shown in Fig. 6, 317 
quantitative results showed that 1 µM of CTD significantly suppressed the expression of 318 
these genes (p < 0.05), which were the same pattern in microarray results. 319 
 320 
3.7. Effects of CTD on neurite outgrowth of SH-SY5Y cells 321 
In order to examine the neurodifferentiative effects of micromolar concentrations of CTD, 322 
we treated differentiating cells with CTD and morphologically evaluated the neurite 323 
outgrowth. As shown in Fig. 7A, neurites in differentiated cells were visualized by 324 
immunofluorescent staining with the neurite marker MAP2 (microtubule-associated protein 325 
2). Quantitative analyses revealed that at least 1 µM of CTD significantly increased neurite 326 
length compared to the control group (Fig. 7B) [F(3, 13) = 12.711, p < 0.01]. The number of 327 
neurites per cell was not significantly changed by CTD (Fig. 7C) [F(3, 13) = 3.345]. 328 
 329 
4. Discussion 330 
In the present study, we investigated whether CTD affected human neuroblastoma 331 
SH-SY5Y cells to obtain information about the risks of neonicotinoids in the human nervous 332 
system. Unexpectedly, CTD dose-dependently increased the number of cells and nAChR 333 
antagonists inhibited the growth stimulating effect of CTD. We clarified some of the 334 
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underlying mechanisms of the effects of CTD mediating intracellular calcium flux, 335 
phosphorylation of signal transduction molecules and alteration of global gene expression. 336 
Although cytotoxic effects of millimolar concentrations of neonicotinoids on SH-SY5Y cells 337 
were previously reported (Skandrani et al., 2006; Şenyildiz et al., 2018), these results firstly 338 
demonstrated that micromolar concentrations have functional effects on human-derived 339 
neuronal cells, in part by changing the intracellular signaling. Taken together, our data would 340 
provide a new perspective into understanding the effects of non-lethal doses of 341 
neonicotinoids on human nervous systems. 342 
One of the interesting findings of this study is the growth stimulating effects of CTD, 343 
consistent with previous work evaluating the effects of nicotine in the same cell line (Serres 344 
and Carney, 2006). At the cellular level, cholinergic signaling by exogenous stimulation 345 
regulates cellular activities such as apoptosis, cell survival, proliferation and differentiation 346 
(Resende and Adhikari, 2009). Excessive amounts of nicotinic agonists are lethal, but 347 
sublethal doses consistently had proliferative effects in nAChR-expressing cell lines such as 348 
HT29 colon cancer cells and A549 lung cancer cells (Wong et al., 2007; Mucchietto et al., 349 
2018). Additionally, activation of nAChRs has neuroprotective effects in SH-SY5Y cells; for 350 
example, nAChRs activation alleviated neurotoxicity of okadaic acid and amyloid-β (Del 351 
Barrio et al., 2011; Xue et al., 2015). Although the proliferation of neural cells was observed 352 
in limited areas in the mature brain, an in vivo study showed that an α7 nicotinic agonist 353 
reactivated adult neurogenesis in cortex and hippocampus in mice (Narla et al., 2013). Taken 354 
together, further studies should be carried out focusing on the effects of neonicotinoids on 355 
proliferative and differentiative neural stem cells in developing brains. 356 
Our results showed that concomitant exposure to nAChR antagonists inhibited the growth 357 
stimulating effects of CTD. Given that these antagonists are active against human nAChRs, 358 
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our findings raise the likelihood that human-type nAChRs could be affected by 359 
neonicotinoids. Neuronal nAChRs are composed of pentamer structure and largely divided 360 
into four groups by subunit composition: (i) α7 homomers, (ii) α4 and β2 heteromers, (iii) α3, 361 
β4 and β2 heteromers and (iv) α2, α4 and β4 heteromers (Albuquerque et al., 2009). To date, 362 
previous studies have reported that CTD modulates electrophysiological responses to 363 
acetylcholine in human embryonic kidney (HEK293) cells expressing human α4β2 nAChRs, 364 
and in Xenopus oocytes expressing rat α7 nAChRs (Li et al., 2011; Cartereau et al., 2018). In 365 
this study, we used human neuroblastoma SH-SY5Y cells expressing α3, α7, β2, and β4 366 
subunits (Groot Kormelink and Luyten, 1997). Our results showed that mecamylamine and 367 
SR 16584 inhibited the increasing of the cell number, indicating that α3β4 nAChRs are 368 
largely responsible for the effects of CTD. As described above, α3β4 nAChRs are frequently 369 
called “ganglion type” nAChRs, but they also play important roles in broad regions of 370 
mammal brain including hippocampus, medial habenula, pineal gland, cerebellum, locus 371 
coeruleus, substantia nigra and ventral tegmental area (Gotti, et al., 2006). Compared to other 372 
types of nAChRs, the current responses of α3β4 nAChRs to nicotinic agonists are slow but 373 
strong and durable (Chavez-Noriega et al., 1997), which may lead to the functional effects 374 
and phenotypic changes observed in this study. A recent study also revealed that the 375 
neonicotinoid IMI facilitates the expression of tyrosine hydroxylase, a marker of 376 
differentiation in PC12D cells mediated by rat α3β4 and α7 nAChRs (Kawahata and 377 
Yamakuni, 2018); thus, human α3β4 nAChRs could be significant to understanding the 378 
unexpected effects of neonicotinoids. 379 
Neuronal nAChRs function as non-selective cation channels permeable to calcium ions. 380 
Cation influx by nAChRs subsequently raises the intracellular calcium concentration by 381 
activating voltage-dependent calcium channels (VDCCs) with membrane depolarization and 382 
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calcium release by ryanodine receptors from endoplasmic reticulum (Shen and Yakel, 2009). 383 
In this study, micromolar concentrations of CTD dose-dependently evoked the transient 384 
increase of intracellular calcium level for a few tens of seconds. These temporal patterns are 385 
very similar to intracellular calcium responses to micromolar concentrations of nicotine; such 386 
responses are partly mediated by α7 nAChRs and depend to a large part on VDCCs 387 
(Dajas-Bailador et al., 2002a; Gilbert et al., 2009). Transcriptome analysis by Kimura-Kuroda 388 
et al., (2016) showed that 1 µM nicotine and two neonicotinoids (ACE and IMI) commonly 389 
altered the gene expression of VDCC subunits in rat cerebellar cells. Another in vivo study 390 
consistently demonstrated that CTD-induced dopamine release in rat striatum is related to 391 
neuronal membrane depolarization (Faro et al., 2012). Our result also showed that gene sets 392 
related “Flux of Ca
2+
,” “Influx of Ca
2+
,” and “Ion homeostasis of cells” were significantly 393 
enriched in the CTD-down-regulated genes, which may be a result of negative feedback by 394 
sustained higher intracellular calcium with membrane depolarization. 395 
Mitogen-activated protein kinases play crucial roles in neural cells for transmitting 396 
exogenous stimulation to intracellular signaling. In particular, ERK regulates cell 397 
proliferation, differentiation, survival, and migration. In this study, we found that CTD 398 
dose-dependently increased the phosphorylation level of ERK, consistent with other studies 399 
in mouse neuroblastoma N1E-115 cells (Tomizawa and Casida, 2002) and SH-SY5Y cells 400 
(Dajas-Bailador et al., 2002b). These studies consistently demonstrated that phosphorylation 401 
states of ERK were altered by nAChR-mediated calcium signaling and membrane 402 
depolarization. In rat PC12h cells, ERK phosphorylation by nicotinic ligands is inhibited by 403 
α3β4 nAChRs (Nakayama et al., 2006) and over-expression of α7 nAChRs promotes the 404 
basal level of p-ERK (Utsugisawa et al., 2002). Our network analyses showed that most of 405 
the down-regulated genes indirectly act upstream of ERK, which may support the modulation 406 
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of ERK activation induced by CTD. It also should be noted that neonicotinoids, including 407 
CTD are immediately metabolized inside the body of mammals, and certain amounts of 408 
metabolites of neonicotinoids are detected in the brain (Fold and Casida, 2006). Other studies 409 
demonstrated that metabolites of IMI had higher affinity for human nAChRs and induced 410 
strong activation of ERK than that of the original compound (Tomizawa and Casida 2002, 411 
2005), indicating that additional studies should be conducted focusing on the potential effects 412 
of metabolites of neonicotinoids. Considering that ERK signaling controls neuroplasticity and 413 
synaptic transmission in the brain (Thomas and Huganir, 2004), we should consider the risks 414 
of neonicotinoids on higher brain function such as learning and memory. 415 
Microarray analyses revealed different aspects of the effects of CTD, indicating that 24 h 416 
exposure of 1 µM CTD could disrupt several sets of gene expression involved in cytoskeleton 417 
regulatory signaling. A series of studies recently showed that α7 nAChRs coupled to 418 
G-proteins and regulated cytoskeletal dynamics and axon growth (King et al., 2015; Kabbani 419 
and Nichols, 2018), suggesting intracellular calcium flux mediated by nAChRs also 420 
associated with morphological changes of neuronal cells. In this study, our data indicated that 421 
down-regulated genes contained significantly enriched biological functions of “Formation of 422 
filopodia,” essential for advancing growth cones to extend neurites at the tip of the axon. It 423 
was also noted that “Axon guidance signaling” was the most significantly enriched pathway 424 
with no activity pattern available and “Differentiation of nervous system” was the 425 
significantly enriched biological function in the down-regulated genes by CTD. Therefore, 426 
we investigated whether CTD had an impact on neurite outgrowth in differentiating 427 
SH-SY5Y cells. We observed increased length and number of neurite in differentiated 428 
SH-SY5Y cells by CTD exposure, both of which disagree with previous studies reporting that 429 
ACE and IMI suppressed neurite outgrowth in rat Purkinje cells (Kimura-Kuroda et al., 2016). 430 
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Furthermore, another study reported that four neonicotinoids had no effect on neurite length 431 
of PC12 cells (Christen et al., 2017). Nordman and Kabbani (2012) showed that nicotinic 432 
agonists inhibited neurite surface area in PC12 cells, whereas a nicotinic antagonist for α7 433 
nAChRs, α-bungarotoxin promoted it. These inconsistencies among studies may reflect 434 
differences in species, cell type, and receptor properties.  435 
In conclusion, the present study demonstrated for the first time that CTD had functional 436 
effects on human neuroblastoma SH-SY5Y cells that resulted in increased cell growth 437 
mediated by human nAChRs. Moreover, our data showed that micromolar concentrations of 438 
CTD acutely disrupted intracellular signaling that led to an influx of intracellular calcium, 439 
phosphorylation of ERK and alteration of global gene expression. Transcriptional and 440 
neuromorphological changes strongly suggest that CTD has impacts on neuronal 441 
differentiation and neurite outgrowth. Taken together, our data provide novel toxicological 442 
information to assess the risk of neonicotinoids on human health by using a human-derived 443 
cell line with neuronal properties. Additional research is needed to understand the risk of 444 
environmentally-relevant doses of neonicotinoids, with a focus on developmental events in 445 
the brain such as neural differentiation, migration, and neural circuit development. 446 
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Figure legends 639 
Fig. 1. Effects of clothianidin (CTD) on the cell growth of SH-SY5Y cells. (A) Cell growth 640 
curve for SH-SY5Y cells exposed to 1 or 100 µM CTD. Relative cell number is determined 641 
as fold change in cell number relative to the number of cells initially plated. (B) 642 
Dose-response curve for the increases of cell number at 24 h of CTD exposure evaluated by 643 
WST-8 assay. Responses are normalized to the maximum response induced by 10 µM CTD 644 
and fitted to the 4-parameter sigmoidal equation. All data points are represented by at least 645 
five independent experiments and values are shown by the mean ± SD, 
†
 p < 0.05 CTD 1 µM 646 
vs. control group, and *p < 0.05, **p < 0.01 CTD 100 µM vs. control group (one-way 647 
ANOVA followed by Dunnett’s post-hoc test).  648 
 649 
Fig. 2. Effects of nicotinic acetylcholine receptors antagonists, (A) 10 µM mecamylamine 650 
(MEC; broad spectrum antagonist), (B) 100 nM methyllycaconitine (MLA; α7 selective 651 
antagonist), (C) 10 µM dihydro-β-erythroidine (DHβE; β2 selective antagonist) and (D) 10 652 
µM SR 16584 (α3β4 selective antagonist) on the growth stimulating effect of 100 µM CTD. 653 
All data are represented by at least five independent experiments and values are shown by the 654 
mean ± SD, *p < 0.05, **p < 0.01 vs. other groups (two-way ANOVA followed by Tukey’s 655 
post-hoc test).  656 
 657 
Fig. 3. Effects of CTD on intracellular calcium level of SH-SY5Y cells evaluated by fluo-4 658 
assay. (A) Time course of changes in the fluorescence intensity of fluo-4 evoked by CTD. 659 
Fluorescence intensity at each time point was normalized to the average level of the baseline 660 
intensity. The summarized data, (B) Fmax-F0 and (C) area under curve were calculated to 661 
quantitate the effect of CTD. F: fluorescence intensity; F0: average level of baseline 662 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
26 
26 
 
fluorescence intensity; Fmax: maximal value of fluorescence intensity after treatment. All 663 
data are represented by at least three independent experiments and values are shown by the 664 
mean ± SD, *p < 0.05, **p < 0.01 vs. control group (one-way ANOVA followed by Dunnett’s 665 
post-hoc test).  666 
 667 
Fig. 4. Effects of CTD on phosphorylation levels of extracellular signal-regulated kinase 1/2 668 
(ERK) on SH-SY5Y cells analyzed by western blotting. (A) Representative images of bands 669 
of phosphorylated ERK (p-ERK) and total ERK on the same membrane. (B) Phosphorylation 670 
levels of ERK after 1 h exposure of CTD were calculated by band intensities of p-ERK 671 
normalized by those of total ERK. All data are represented by at least three independent 672 
experiments and values are shown by the mean ± SD, *p < 0.05 vs. control group (one-way 673 
ANOVA followed by Dunnett’s post-hoc test). 674 
 675 
Fig. 5. Canonical pathways and a gene network of 151 down-regulated genes (>1.5-fold) 676 
altered by 24 h exposure of 1 µM CTD identified by ingenuity pathway analysis (IPA) 677 
software. (A) Signaling pathways significantly enriched by Fisher's exact test were 678 
summarized. Solid and dotted squares showed pathways related to neural and cytoskeletal 679 
function. (B) A gene network map illustrated interactions of down-regulated genes (green 680 
colored) and other molecules. 681 
 682 
Fig. 6. Validation of microarray results using quantitative reverse transcription PCR. Gene 683 
expression levels of neuronal differentiation 4 (NEUROD4), adrenoceptor beta 2 (ADRB2), 684 
neurotensin (NTS) in the control (white bar) and of CTD-exposed group (1 µM, blue bar) 685 
were calculated relative to the housekeeping gene, glyceraldehyde-3-phosphate 686 
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dehydrogenase (GAPDH) by comparison to the control group. All data are represented by at 687 
least three independent experiments and values are shown by the mean ± SD, *p < 0.05 vs. 688 
control group (Welch’s t test). 689 
 690 
Fig. 7. Effects of CTD on neurite outgrowth in differentiating SH-SY5Y cells. Cells were 691 
induced to differentiate for 6 days with or without CTD exposure. (A)Representative images 692 
of immunofluorescent staining of a neurite maker, MAP2 (microtubule-associated protein 2: 693 
red) with DAPI cell nuclear staining (blue) in the control, CTD 1 µM, CTD 10 µM and 694 
CTD 100 µM group. The average of (B) neurite length and (C) number of neurites per cell 695 
were measured by the image analysis. Bar = 100 µm. All data are represented by at least three 696 
independent experiments and values are shown by the mean ± SD, *p < 0.05, **p < 0.01 vs. 697 
control group (one-way ANOVA followed by Dunnett’s post-hoc test).698 
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Table1. Primer sequences used in quantitative reverse transcription PCR  
Gene Symbol Gene ID Direction Primer sequence (5'-3') 
NEUROD4 NM_021191.3 foword gggagagctagtcaacacac 
(neuronal differentiation 4) reverse ttgggaccccttctcttagg 
ADRB2 NM_000024.5 foword ggattgtgtcaggccttacc 
(adrenoceptor beta 2) reverse gatcaccaggggaacgtaga 
NTS NM_006183.5 foword ccttcagtgtgcttctgac 
(neurotensin) reverse gcagagtcatcttccaagag 
GAPDH NM_001256799.2 foword ccaccaactgcttagcac 
(glyceraldehyde-3-phosphate dehydrogenase) reverse catcacgccacagtttcc 
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Table 2. Top 25 of biological functions of 151 down-regulated genes  
Functions Annotation p-Value Predicted 
Activation State 
Activation 
z-score 
Number of 
Molecules 
 
Size of body 9.46E-05 Decreased -4.088 18  
Formation of filopodia 4.74E-03 Decreased -2.219 5  
Flux of Ca
2+
 5.64E-03 Decreased -2.192 7  
Binding of leukocyte cell lines 4.57E-04 Decreased -2.000 4  
Hydrolysis of nucleotide 6.18E-03   -1.949 4  
Influx of Ca
2+
 1.17E-02   -1.932 5  
Ion homeostasis of cells 5.18E-03   -1.890 11  
Adhesion of blood cells 7.08E-03   -1.857 8  
Adhesion of tumor cell lines 7.04E-03   -1.680 7  
Adhesion of immune cells 1.51E-02   -1.598 7  
Leukocyte migration 4.62E-03   -1.341 15  
Permeability of vascular system 1.52E-04   -1.164 7  
Angiogenesis of tumor 8.02E-03   -1.131 4  
Binding of hematopoietic cell lines 5.26E-05   -1.109 5  
Brain lesion 4.55E-03   -0.927 15  
Atherosclerosis 4.39E-03   -0.878 10  
Growth of vessel 7.45E-04   -0.796 6  
Advanced malignant tumor 8.25E-03   -0.594 15  
Quantity of neurons 1.16E-02   -0.527 8  
Cancer of cells 1.29E-02   -0.384 46  
Neoplasia of cells 4.51E-03   -0.350 49  
Behavior 7.85E-03   -0.046 16  
Lymphatic system tumor 8.34E-03   0.926 24  
Differentiation of nervous system 1.42E-02   1.342 9  
Organismal death 9.36E-03 Increased 4.755 30  
activation z-score; >2.0 or < -2.0 is significantly predictive  
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